A phase 1a/1b dose escalation and expansion study to evaluate the effect of HDP-101 for the treatment of Multiple Myeloma
Phase of Trial: Phase I
Latest Information Update: 10 Oct 2019
Price : $35 *
At a glance
- Drugs HDP 101 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; First in man
- 10 Oct 2019 According to an Heidelberg Pharma AG media release, the company is expected to file for a clinical trial application in the second half of 2020.
- 21 May 2019 According to an Heidelberg Pharma AG media release, the company aim to treat the first multiple myeloma patient with their first ATAC candidate (HDP-101) in 2020.
- 21 Mar 2019 According to a Heidelberg Pharma media release, pplications for the Phase Ia (dose escalation) and Phase Ib (dose expansion) will be submitted simultaneously in the USA and Germany.